Sequential morphological changes in follow-up CT of pulmonary mucormycosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choo, Ji Yung | - |
dc.contributor.author | Park, Chang Min | - |
dc.contributor.author | Lee, Hyun-Ju | - |
dc.contributor.author | Lee, Chang Hyun | - |
dc.contributor.author | Goo, Jin Mo | - |
dc.contributor.author | Im, Jung-Gi | - |
dc.date.accessioned | 2021-09-05T12:34:53Z | - |
dc.date.available | 2021-09-05T12:34:53Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 1305-3825 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/99617 | - |
dc.description.abstract | PURPOSE We aimed to describe the computed tomography (CT) features of pulmonary mucormycosis including sequential changes between follow-ups. MATERIALS AND METHODS Between June 2001 and May 2011, five patients (three males and two females; median age, 43 years; age range, 13-73 years) who had been pathologically diagnosed with pulmonary mucormycosis constituted our study population. Their clinical and CT features including sequential changes over follow-ups were evaluated retrospectively. RESULTS All patients were immunocompromised due to either hematologic diseases (n=3), diabetes mellitus (n=1), or steroid administration for autoimmune hepatitis (n=1). All patients had symptoms such as fever (n=5), tachycardia (n=1), or pleuritic chest pain (n=1) on admission. Regarding the clinical outcome after treatment, one patient died, and the remaining four recovered from the disease. In terms of initial CT features, the morphologies of pulmonary mucormycosis included a single mass (n=3), consolidation (n=1), or multiple masses (n=1). There were seven pulmonary lesions in total, 3-7 cm in size, which showed a CT halo sign (n=3), reversed-halo sign (n=2), or air-fluid levels (n=2). On follow-up CTs, the lesions of all patients contained necrosis. All three patients with a mass or masses with a CT halo sign on initial CT had a decreased surrounding halo followed by central necrosis, and the lesions gradually decreased in size on recovery. CONCLUSION Pulmonary mucormycosis usually manifests as a mass or masses with a halo or reversed-halo sign on the initial CT scan followed by a decreased extent of surrounding ground-glass opacities with the development of internal necrosis during follow-up. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AVES | - |
dc.subject | RADIOLOGIC FINDINGS | - |
dc.subject | ASPERGILLOSIS | - |
dc.subject | SPECTRUM | - |
dc.title | Sequential morphological changes in follow-up CT of pulmonary mucormycosis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choo, Ji Yung | - |
dc.identifier.doi | 10.5152/dir.2013.13183 | - |
dc.identifier.scopusid | 2-s2.0-84891723794 | - |
dc.identifier.wosid | 000331468700006 | - |
dc.identifier.bibliographicCitation | DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, v.20, no.1, pp.42 - 46 | - |
dc.relation.isPartOf | DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY | - |
dc.citation.title | DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 42 | - |
dc.citation.endPage | 46 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | RADIOLOGIC FINDINGS | - |
dc.subject.keywordPlus | ASPERGILLOSIS | - |
dc.subject.keywordPlus | SPECTRUM | - |
dc.subject.keywordAuthor | mucormycosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.